JPH09241156A - Blood flow promotor and preparation for external use for skin containing the same - Google Patents
Blood flow promotor and preparation for external use for skin containing the sameInfo
- Publication number
- JPH09241156A JPH09241156A JP7966696A JP7966696A JPH09241156A JP H09241156 A JPH09241156 A JP H09241156A JP 7966696 A JP7966696 A JP 7966696A JP 7966696 A JP7966696 A JP 7966696A JP H09241156 A JPH09241156 A JP H09241156A
- Authority
- JP
- Japan
- Prior art keywords
- arginine
- blood flow
- ester
- acid
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は経時安定性、安全
性、経皮吸収性及び細胞膜親和性に優れた血流促進剤及
びそれを有効成分として配合した皮膚外用剤、化粧料特
に老化防止用化粧料、頭皮用化粧料、養毛・育毛剤に関
する。TECHNICAL FIELD The present invention relates to a blood flow promoter having excellent stability over time, safety, percutaneous absorption and affinity for cell membranes, and a skin external preparation containing the same as an active ingredient, a cosmetic, especially for antiaging. The present invention relates to cosmetics, scalp cosmetics, and hair-growth / hair-growth agents.
【０００２】[0002]
【従来の技術】従来、美肌作用を有するものとして種々
の成分が皮膚外用剤及び化粧料に用いられてきた。この
中で、血流促進剤は、真皮及び表皮細胞への血流を促進
することにより、真皮線維芽細胞を賦活化してしわの発
生を防止したり、しわの改善効果を発揮したり、皮膚細
胞層への栄養成分や水分を充分に補給し組織内からエモ
リエント効果，保湿効果を発揮したり、新陳代謝が活発
になることによりくすみを改善する効果を発揮する。2. Description of the Related Art Heretofore, various components have been used in external preparations for skin and cosmetics as those having a skin beautifying effect. Among these, the blood flow promoting agent, by promoting the blood flow to the dermis and epidermal cells, to activate the dermal fibroblasts to prevent the generation of wrinkles, or to exert the effect of improving wrinkles, skin It provides emollient and moisturizing effects from within tissues by adequately replenishing nutrients and water to the cell layer, and improves dullness by activating metabolism.
【０００３】また、ふけ、かゆみ、脱毛等の頭皮にかか
る種々の疾患の原因のひとつとして、頭皮の血流不良が
指摘されており、血流促進効果を有する皮膚外用剤の適
用がなされてきた。Poor blood flow in the scalp has been pointed out as one of the causes of various diseases related to the scalp such as dandruff, itch, and hair loss, and an external preparation for skin having a blood flow promoting effect has been applied. .
【０００４】さらに、養毛・育毛を目的とする養毛・育
毛剤には、従来から酢酸ｄｌ−α−トコフェロールなど
の合成化学物質やセンブリ抽出液等の血流促進剤が有効
成分として用いられてきた。[0004] Further, synthetic hairs such as dl-α-tocopheryl acetate and blood flow promoters such as cembly extract have been used as active ingredients for hair growth and hair growth agents for hair growth and hair growth. Came.
【０００５】一方、Ｌ−アルギニンは、ＮＯ合成酵素と
反応し、血流促進効果を有するＮＯラジカルを生成する
ことが知られている（化学と工業，Vol.４８No.５，１
９９５）。そこで、アルギニン及びそのアルキルエステ
ルを有効成分とする養毛剤（ＷＯ９４／０９７５０）、
アルギニン及びそのエステルを配合した化粧料（ＷＯ９
５／１５１４７）が開示されている。On the other hand, L-arginine is known to react with NO synthase to produce NO radicals having a blood flow promoting effect (Chemicals and Industry, Vol. 48 No. 5, 1).
995). Therefore, a hair nourishing agent (WO94 / 09750) containing arginine and its alkyl ester as an active ingredient,
Cosmetics containing arginine and its ester (WO9
5/15147) is disclosed.
【０００６】[0006]
【発明が解決しようとする課題】しかしながら、Ｌ−ア
ルギニンは塩基性のアミノ酸であり、血流促進剤等の有
効成分として使用するには、経皮で皮膚刺激の原因とな
ったり、安定な製剤が得られない等の問題があった。However, L-arginine, which is a basic amino acid, causes skin irritation by percutaneous use and is a stable preparation for use as an active ingredient such as a blood flow promoter. There was a problem such as not being able to obtain.
【０００７】さらに、Ｌ−アルギニンは、水溶性の性質
を有しているため、細胞膜透過性が低く、皮膚外用剤等
の製剤に配合して経皮投与を行っても、有効量のＬ−ア
ルギニンを配合することは困難であった。Furthermore, since L-arginine has a water-soluble property, it has low cell membrane permeability, and even if it is transdermally administered to a preparation such as a skin external preparation, an effective amount of L-arginine is obtained. It was difficult to mix arginine.
【０００８】そこで、本発明はこのような課題を解決
し、経皮投与した場合の安全性及び経時安定性が良好
で、高い細胞膜親和性を有し、経皮吸収性に優れた血流
促進剤、皮膚外用剤、老化防止用化粧料、頭皮用化粧
料、養毛・育毛剤を得ることを目的とした。Therefore, the present invention has solved such problems, has good safety and stability over time when transdermally administered, has a high affinity for cell membranes, and promotes blood flow with excellent transdermal absorbability. The purpose of the present invention is to obtain an agent for external use on the skin, a cosmetic for preventing aging, a cosmetic for scalp, and a hair nourishing / hair-growing agent.
【０００９】[0009]
【課題を解決するための手段】本発明の課題を解決する
ため本発明においては、Ｌ−アルギニンの炭素数６〜２
０のアルキル若しくはアルケニルエステル、リン脂質エ
ステル、スフィンゴシン及びその誘導体のエステル、糖
脂質エステル、糖エステル、ステロールエステルを有効
成分とする血流促進剤を用いた。In order to solve the problems of the present invention, in the present invention, L-arginine has 6 to 2 carbon atoms.
A blood flow promoting agent containing an alkyl or alkenyl ester of 0, phospholipid ester, ester of sphingosine and its derivative, glycolipid ester, sugar ester, and sterol ester as active ingredients was used.
【００１０】Ｌ−アルギニンのアルキル若しくはアルケ
ニルエステルに用いられるアルキル基，アルケニル基と
しては、炭素数６〜２０の分岐又は直鎖のアルキル基若
しくはアルケニル基が挙げらる。このようなＬ−アルギ
ニンのアルキルエステルとしては、Ｌ−アルギニンオク
チルエステルのような直鎖脂肪族エステル、Ｌ−アルギ
ニンイソステアリルエステルのような分岐鎖脂肪族エス
テル、Ｌ−アルギニンフェニルエチルエステルのような
フェニルアルキルエステル等が、アルケニルエステルと
してはＬ−アルギニンオレイルエステル等が例示され
る。Examples of the alkyl group and alkenyl group used for the alkyl or alkenyl ester of L-arginine include a branched or linear alkyl group or alkenyl group having 6 to 20 carbon atoms. Examples of the alkyl ester of L-arginine include straight chain aliphatic esters such as L-arginine octyl ester, branched chain aliphatic esters such as L-arginine isostearyl ester, and L-arginine phenylethyl ester. Phenyl alkyl ester and the like are exemplified, and as alkenyl ester, L-arginine oleyl ester and the like are exemplified.
【００１１】Ｌ−アルギニンのリン脂質エステルに用い
られるリン脂質としては、ホスファチジン酸，ホスファ
チジルエタノールアミン，ホスファチジルセリン，ホス
ファチジルイノシトール，ホスファチジルグリセロー
ル，ホスファチジルコリン等のグリセロリン脂質があげ
られる。Examples of the phospholipid used for the phospholipid ester of L-arginine include glycerophospholipids such as phosphatidic acid, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol and phosphatidylcholine.
【００１２】さらに、Ｌ−アルギニンのリン脂質エステ
ルに用いられるリン脂質としては、スフィンゴミエリ
ン，セラミドホスホエタノールアミン，セラミドホスホ
イノシトールのようなスフィンゴリン脂質を用いること
もできる。Further, as the phospholipid used for the phospholipid ester of L-arginine, sphingolipids such as sphingomyelin, ceramide phosphoethanolamine and ceramide phosphoinositol can be used.
【００１３】Ｌ−アルギニンの糖脂質エステルに用いら
れる糖脂質としては、グリセロ糖脂質，スフィンゴ糖脂
質のいずれでも良い。グリセロ糖脂質としては、モノア
シルグリコシルグリセロール，ジアシルガラクトシルグ
リセロール，グルコサミニルホスファチジルグリセロー
ル等が、また、スフィンゴ糖脂質の例としては、セレブ
ロシド類，スルファチド類，セラミドオリゴヘキソシド
類，グロボシド類，ガングリオシド類等が挙げられる。The glycolipid used in the glycolipid ester of L-arginine may be either a glyceroglycolipid or a glycosphingolipid. Glyceroglycolipids include monoacylglycosylglycerol, diacylgalactosylglycerol, glucosaminylphosphatidylglycerol, and examples of glycosphingolipids include cerebrosides, sulfatides, ceramide oligohexosides, globosides, gangliosides. And the like.
【００１４】Ｌ−アルギニンの糖エステルに用いられる
糖としては、細胞膜親和性の点から単糖類又は二糖類〜
三糖類くらいのオリゴ糖が好ましい。本発明の目的に
は、エリスロース，トレオース等のテトロース類、アラ
ビノース，キシロース，リボース等のペントース類、ガ
ラクトース，グルコース，マンノース，プシコース，フ
ルクトース等のヘキソース類、N-アセチルガラクトサミ
ン，N-アセチルグルコサミン，マンノサミン等のアミノ
糖類、マルトース，ラクトース，ショ糖，セロビオース
等の二糖類、セロトリオース等の三糖類などが例示され
る。The sugar used in the sugar ester of L-arginine is a monosaccharide or disaccharide from the viewpoint of cell membrane affinity.
Oligosaccharides such as trisaccharides are preferred. For the purpose of the present invention, tetroses such as erythrose and threose, pentoses such as arabinose, xylose and ribose, hexoses such as galactose, glucose, mannose, psicose and fructose, N-acetylgalactosamine, N-acetylglucosamine, Examples include amino sugars such as mannosamine, disaccharides such as maltose, lactose, sucrose and cellobiose, and trisaccharides such as cellotriose.
【００１５】Ｌ−アルギニンのステロールエステルに用
いられるステロールとしては、動物起源のもの，植物起
源のもの及び合成によるもののいずれを用いても良い。
かかるステロールとしては、コレステロール，ラノステ
ロール，フィトステロール，シトステロール，スチグマ
ステロール，カンペステロール，デスモステロール及び
これらステロールの誘導体等を挙げることができる。The sterol used in the sterol ester of L-arginine may be of animal origin, plant origin or synthetic origin.
Examples of such sterols include cholesterol, lanosterol, phytosterol, sitosterol, stigmasterol, campesterol, desmosterol, and derivatives of these sterols.
【００１６】以上例示したアルギニンのエステル類は、
従来公知のエステル化反応又はエステル交換反応により
合成することができる。The arginine esters exemplified above are:
It can be synthesized by a conventionally known esterification reaction or transesterification reaction.
【００１７】たとえば、Ｌ−アルギニンのホスファチジ
ルエステルは、ホスホリパーゼＡ１によるエステル交換
反応により、効率よくホスファチジン酸の１位にエステ
ル結合させることができる。For example, a phosphatidyl ester of L-arginine can be efficiently ester-bonded to the 1-position of phosphatidic acid by a transesterification reaction with phospholipase A1.
【００１８】また、Ｌ−アルギニンの糖エステルは、た
とえばＬ−アルギニンをエステル化し、これと糖とを水
酸化ナトリウム等のアルカリ触媒存在下にて反応させ、
エステル交換反応等により合成することができる。な
お、副生成物のアルコールを系から除去すると、反応を
効率よく進ませることができる。The sugar ester of L-arginine is obtained by, for example, esterifying L-arginine, and reacting this with sugar in the presence of an alkali catalyst such as sodium hydroxide.
It can be synthesized by a transesterification reaction or the like. When the alcohol by-product is removed from the system, the reaction can proceed efficiently.
【００１９】さらに、Ｌ−アルギニンのステロールエス
テルは、たとえば無触媒又はパラトルエンスルホン酸，
塩化スズ等の触媒の存在下に、Ｌ−アルギニン及びステ
ロールの混合物を約１００〜２５０℃程度に加熱すれば
よい。この反応の終点は、酸価を測定することにより知
ることができる。Further, the sterol ester of L-arginine is, for example, uncatalyzed or paratoluenesulfonic acid,
The mixture of L-arginine and sterol may be heated to about 100 to 250 ° C. in the presence of a catalyst such as tin chloride. The end point of this reaction can be known by measuring the acid value.
【００２０】[0020]
【発明の実施の形態】本発明において、上記Ｌ−アルギ
ニンエステルを有効成分とする血流促進剤の皮膚外用
剤，化粧料，養毛剤等への配合量は、０．１〜５重量％
が適当である。BEST MODE FOR CARRYING OUT THE INVENTION In the present invention, the amount of the blood flow promoting agent containing the above-mentioned L-arginine ester as an active ingredient in skin external preparations, cosmetics, hair nourishing agents, etc. is 0.1 to 5% by weight.
Is appropriate.
【００２１】本発明にかかる皮膚外用剤，化粧料，養毛
剤等は、ローション，油剤，乳剤，クリーム，軟膏等の
剤型を、またボトル，ジャー，チューブ，フォーム，ゲ
ル，スプレー等の形態をとることができる。また、本発
明における皮膚外用剤等の適用部位は、顔面及び頭皮の
みならず、肩，腕，腹，背中，脚部等全身に使用でき
る。The external preparation for skin, cosmetics, hair nourishing agent and the like according to the present invention takes the form of lotions, oils, emulsions, creams, ointments and the like, and forms such as bottles, jars, tubes, foams, gels and sprays. be able to. Further, the application site of the external preparation for skin or the like in the present invention can be used not only on the face and scalp but also on the whole body such as shoulders, arms, abdomen, back and legs.
【００２２】本発明においてはさらに必要に応じて、本
発明の効果を損なわない範囲で、化粧品、医薬品等に一
般に用いられている各種成分、すなわち、アボカド油，
パーム油，ピーナッツ油，コメヌカ油，ホホバ油，オレ
ンジラフィー油，マカデミアナッツ油，スクワラン，月
見草油，セサミ油，サンフラワー油，サフラワー油，キ
ャローラ油，カルナウバワックス，パラフィンワック
ス，ラノリン，リンゴ酸ジイソステアリル，イソステア
リルアルコール，流動パラフィン等の油分、グリセリ
ン，ジグリセリン，ポリグリセリン，ソルビット，ポリ
エチレングリコール，1,3-ブチレングリコール，コラー
ゲン，ヒアルロン酸等の保湿剤、ビタミンＡ油，レチノ
ール，酢酸レチノール等のビタミンＡ類、リボフラビ
ン，酪酸リボフラビン等のビタミンＢ2類、塩酸ピリドキ
シン等のビタミンＢ6類、Ｌ−アスコルビン酸，Ｌ−アス
コルビルリン酸マグネシウム，Ｌ−アスコルビン酸ナト
リウム等のビタミンＣ類、パントテン酸カルシウム，パ
ントテニルアルコール，パントテニルエチルエーテル，
アセチルパントテニルエチルエーテル等のパントテン酸
類、エルゴカルシフェロール，コレカルシフェロール等
のビタミンＤ類、ニコチン酸，ニコチン酸アミド，ニコ
チン酸ベンジル等のニコチン酸類、α−トコフェロー
ル，酢酸トコフェロール等のビタミンＥ類、ビタミンＰ、
ビオチン等のビタミン類、２−ヒドロキシ−４−メトキ
シベンゾフェノン，２−ヒドロキシ−４−メトキシベン
ゾフェノン−５−スルホン酸，２−ヒドロキシ−４−メ
トキシベンゾフェノン−５−スルホン酸ナトリウム等の
ベンゾフェノン誘導体、パラアミノ安息香酸，パラアミ
ノ安息香酸エチル，パラジメチルアミノ安息香酸オクチ
ル等のパラアミノ安息香酸誘導体、パラメトキシ桂皮酸
−２−エチルヘキシル，ジパラメトキシ桂皮酸モノ−２
−エチルヘキサン酸グリセリル等のメトキシ桂皮酸誘導
体類、サリチル酸オクチル，サリチル酸ミリスチル等の
サリチル酸誘導体、ウロカニン酸、４−tert−ブチルー
４'ーメトキシジベンゾイルメタン、２−（２'−ヒドロ
キシ−５'−メチルフェニル）ベンゾトリアゾール等の
紫外線吸収剤、グアガム，ローカストビーンガム，カラ
ギーナン，クインスシード，ペクチン，マンナン等の植
物系天然多糖類、キサンタンガム，デキストラン，カー
ドラン等の微生物系天然多糖類、ゼラチン，カゼイン，
アルブミン，コラーゲン等の動物系高分子、メチルセル
ロース，エチルセルロース，ヒドロキシエチルセルロー
ス，ヒドロキシプロピルセルロース，カルボキシメチル
セルロース等のセルロース系半合成高分子、可溶性デン
プン，カルボキシメチルデンプン，メチルデンプン等の
デンプン系半合成高分子、アルギン酸プロピレングリコ
ールエステル，アルギン酸塩等のアルギン酸系半合成高
分子、ポリビニルアルコール，ポリビニルピロリドン，
カルボキシビニルポリマー，ポリアクリル酸ナトリウ
ム，ポリエチレンオキサイド等の合成高分子、ベントナ
イト，ラポナイト，コロイダルアルミナ等の無機物系高
分子等の水溶性高分子、ジブチルヒドロキシトルエン，
ブチルヒドロキシアニソール，没食子酸エステル等の酸
化防止剤、高級脂肪酸石鹸，アルキル硫酸エステル塩，
ポリオキシエチレンアルキルエーテル硫酸塩，アシルメ
チルタウリン塩，アルキルエーテルリン酸エステル塩，
アシルアミノ酸塩等のアニオン界面活性剤、塩化アルキ
ルトリメチルアンモニウム，塩化ジアルキルジメチルア
ンモニウム，塩化ベンザルコニウム等のカチオン界面活
性剤、アルキルジメチルアミノ酢酸ベタイン，アルキル
アミドジメチルアミノ酢酸ベタイン，２−アルキル−Ｎ
−カルボキシメチル−Ｎ−ヒドロキシエチルイミダゾリ
ニウムベタインなどの両性界面活性剤、ポリオキシエチ
レン型ノニオン界面活性剤、アルコールエステル型ノニ
オン界面活性剤等の界面活性剤、エチレンジアミン四酢
酸ナトリウム塩，ポリリン酸ナトリウム，クエン酸，メ
タリン酸ナトリウム，コハク酸，グルコン酸等の金属イ
オン封鎖剤、胎盤抽出物，ソウハクヒエキス，グルタチ
オン，コウジ酸及びその誘導体類，ハイドロキノン配糖
体等のハイドロキノン及びその誘導体類等の美白剤、グ
リチルリチン酸，グリチルレチン酸，アラントイン，ア
ズレン，ヒドロコルチゾン，ε−アミノカプロン酸等の
抗炎症剤、酸化亜鉛，アラントインヒドロキシアルミニ
ウム，塩化アルミニウム，タンニン酸，クエン酸，乳酸
等の収れん剤、ミノキシジル，セファランチン，塩化カ
ルプロニウム，ノニル酸バニルアミド等の育毛・養毛成
分、メントール，カンフル等の清涼化剤、塩酸ジフェン
ヒドラミン，マレイン酸クロルフェニラミン等の抗ヒス
タミン剤、エストラジオール，エストロン，エチニルエ
ストラジオール等の皮脂抑制剤、サリチル酸，レゾルシ
ン等の角質剥離・溶解剤、パラヒドロキシ安息香酸エチ
ル，パラヒドロキシ安息香酸メチル，パラヒドロキシ安
息香酸ブチル，パラヒドロキシ安息香酸プロピル，エチ
レングリコールモノフェニルエーテル等の抗菌防腐剤、
グリセリン，カンファー等の温感剤、α−ヒドロキシ酸
類等が配合できる。In the present invention, if necessary, various components generally used in cosmetics, pharmaceuticals, etc., that is, avocado oil, within a range that does not impair the effects of the present invention,
Palm oil, peanut oil, rice bran oil, jojoba oil, orange luffy oil, macadamia nut oil, squalane, evening primrose oil, sesame oil, sunflower oil, safflower oil, carola oil, carnauba wax, paraffin wax, lanolin, dimalate Oil components such as isostearyl, isostearyl alcohol, liquid paraffin, glycerin, diglycerin, polyglycerin, sorbit, polyethylene glycol, 1,3-butylene glycol, collagen, moisturizers such as hyaluronic acid, vitamin A oil, retinol, retinol acetate vitamin a, riboflavin, vitamin B 2 such as riboflavin butyrate and the like, vitamin B 6 such as pyridoxine hydrochloride, L- ascorbic acid, magnesium L- ascorbyl phosphate, vitamin C such as sodium L- ascorbate , Calcium pantothenate, pantothenyl alcohol, pantothenyl ethyl ether,
Pantothenic acids such as acetyl pantothenyl ethyl ether, vitamin Ds such as ergocalciferol, cholecalciferol, nicotinic acids such as nicotinic acid, nicotinic acid amide, benzyl nicotinate, vitamin Es such as α-tocopherol and tocopherol acetate, Vitamin P,
Vitamin such as biotin, 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid, benzophenone derivative such as sodium 2-hydroxy-4-methoxybenzophenone-5-sulfonate, para-aminobenzoic acid Acid, paraaminobenzoic acid derivatives such as ethyl paraaminobenzoate, octyl paradimethylaminobenzoate, 2-ethylhexyl paramethoxycinnamate, mono-2 diparamethoxycinnamic acid
-Methoxycinnamic acid derivatives such as glyceryl ethylhexanoate, salicylic acid derivatives such as octyl salicylate and myristyl salicylate, urocanic acid, 4-tert-butyl-4'-methoxydibenzoylmethane, 2- (2'-hydroxy-5'- UV absorbers such as methylphenyl) benzotriazole, natural plant polysaccharides such as guar gum, locust bean gum, carrageenan, quince seed, pectin and mannan, microbial natural polysaccharides such as xanthan gum, dextran and curdlan, gelatin, casein ，
Animal-based polymers such as albumin and collagen, cellulosic semi-synthetic polymers such as methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose and carboxymethyl cellulose, and starch-based semi-synthetic polymers such as soluble starch, carboxymethyl starch and methyl starch, Alginic acid propylene glycol ester, alginic acid-based semi-synthetic polymers such as alginate, polyvinyl alcohol, polyvinylpyrrolidone,
Synthetic polymers such as carboxyvinyl polymer, sodium polyacrylate, polyethylene oxide, water-soluble polymers such as bentonite, laponite, inorganic polymers such as colloidal alumina, dibutylhydroxytoluene,
Butyl hydroxyanisole, antioxidants such as gallic acid ester, higher fatty acid soap, alkyl sulfate ester salt,
Polyoxyethylene alkyl ether sulfate, acylmethyl taurine salt, alkyl ether phosphate salt,
Anionic surfactants such as acylamino acid salts, cationic surfactants such as alkyltrimethylammonium chloride, dialkyldimethylammonium chloride, and benzalkonium chloride, alkyldimethylaminoacetic acid betaine, alkylamide dimethylaminoacetic acid betaine, 2-alkyl-N
-Carboxymethyl-N-hydroxyethylimidazolinium betaine and other amphoteric surfactants, polyoxyethylene type nonionic surfactants, alcohol ester type nonionic surfactants and other surfactants, ethylenediaminetetraacetic acid sodium salt, sodium polyphosphate , Whitening of sequestering agents such as citric acid, sodium metaphosphate, succinic acid, gluconic acid, placenta extract, sow syrup extract, glutathione, kojic acid and its derivatives, hydroquinone such as hydroquinone glycoside and its derivatives Agents, anti-inflammatory agents such as glycyrrhizinic acid, glycyrrhetinic acid, allantoin, azulene, hydrocortisone, and ε-aminocaproic acid, astringents such as zinc oxide, allantoin hydroxyaluminum, aluminum chloride, tannic acid, citric acid, and lactic acid; Hair growth and nourishing ingredients such as xidyl, cepharanthin, carpronium chloride, nonyl acid vanilamide, refreshing agents such as menthol and camphor, antihistamines such as diphenhydramine hydrochloride and chlorpheniramine maleate, sebum inhibitors such as estradiol, estrone and ethinyl estradiol Keratin exfoliating and dissolving agents such as salicylic acid and resorcin, antibacterial preservatives such as ethyl parahydroxybenzoate, methyl parahydroxybenzoate, butyl parahydroxybenzoate, propyl parahydroxybenzoate and ethylene glycol monophenyl ether,
Warming sensitizers such as glycerin and camphor, α-hydroxy acids and the like can be added.
【００２３】さらに、細胞賦活，保湿，血行促進，抗炎
症，収れん，抗菌，抗酸化，皮脂抑制作用等の生理活性
を有するアルニカ，アロエ，イタドリ，イラクサ，ウイ
キョウ，エンメイソウ，オウバク，オランダガラシ，カ
キドオシ，カミツレ，カンゾウ，キナ，キンギンカ，キ
ュウリ，クジン，ゲンチアナ，ゲンノショウコ，ゴボ
ウ，コウスイハッカ，サンショウ，ジュウヤク，ショウ
キョウ，シラカンバ，スギナ，セイヨウキズタ，セイヨ
ウノコギリソウ，セージ，センブリ，タイム，チョウ
ジ，チンピ，トウガラシ，トウキンセンカ，トウキ，ト
ウヒ，ニンジン，ニンニク，ノイチゴ，パセリ，ハッ
カ，ハマボウフウ，ハマメリス，バラ，フキタンポポ，
ヘンナ，ボダイジュ，ホップ，ホホバ，マルメロ，マロ
ニエ，ヤグルマギク，ヤドリギ，ユーカリ，ユキノシ
タ，ユリ，ラベンダー，ローズマリー等の植物抽出物及
びこれらの抽出物の分画，精製物を血流促進剤と併用す
ることにより、相乗効果を発揮する。Furthermore, arnica, aloe, knotweed, nettle, fennel, gallgrass, oak, Dutch pepper, oysterfish have physiological activities such as cell activation, moisturizing, blood circulation promotion, anti-inflammatory, astringent, antibacterial, antioxidative and sebum suppressing action. , Chamomile, licorice, chrysanthemum, goldfish, cucumber, kujin, gentian, gennoshoko, burdock, koisu mint, salamander, sycamore, ginger, birch, horsetail, euglena, yarrow, sage, senburi, thyme, butterfly, Capsicum, spruce quince, spruce, spruce, carrot, garlic, strawberry, parsley, peppermint, hamaboufu, hamameris, rose, coltsfoot,
Plant extracts such as henna, bodaiju, hops, jojoba, quince, horse chestnut, cornflower, mistletoe, eucalyptus, yukinoshita, lily, lavender, rosemary, etc., and fractions and purified products of these extracts are used in combination with a blood flow promoter. By doing so, a synergistic effect is exhibited.
【００２４】[0024]
【実施例】さらに本発明の特徴について、実施例により
詳細に説明する。EXAMPLES Further, the features of the present invention will be described in detail with reference to examples.
【００２５】 ［実施例１］液状皮膚外用剤 (1)グリセリン ５．０(重量％) (2)プロピレングリコール ４．０ (3)エタノール １０．０ (4)Ｌ−アルギニン ホスファチジルセリンエステル ０．５ (5)精製水 ８０．５ (4)を(3)に溶解して(5)に加え、(1),(2)を順次添加し、
混合，均一化する。[Example 1] Liquid external preparation for skin (1) Glycerin 5.0 (% by weight) (2) Propylene glycol 4.0 (3) Ethanol 10.0 (4) L-arginine phosphatidylserine ester 0.5 (5) Purified water 80.5 Dissolve (4) in (3) and add to (5), then add (1) and (2) sequentially,
Mix and homogenize.
【００２６】 ［実施例２］化粧水 (1)1,3-ブチレングリコール ３．０(重量％) (2)ソルビトール ２．０ (3)エタノール １０．０ (4)カルボキシビニルポリマー１重量％水溶液 １０．０ (5)Ｌ−アルギニンラウリルエステル ０．３ (6)香料 ０．１ (7)精製水 ７４．６ (6)を(3)に溶解して(7)に加え、(1),(2),(5)を順次添加
して混合した後、(4)を加え、混合，均一化する。[Example 2] Lotion (1) 1,3-butylene glycol 3.0 (wt%) (2) sorbitol 2.0 (3) ethanol 10.0 (4) carboxyvinyl polymer 1 wt% aqueous solution 10.0 (5) L-arginine lauryl ester 0.3 (6) Perfume 0.1 (7) Purified water 74.6 (6) is dissolved in (3) and added to (7), (1), After adding (2) and (5) sequentially and mixing, add (4) and mix and homogenize.
【００２７】 ［実施例３］Ｏ／Ｗ型乳剤性軟膏 (1)白色ワセリン ２５．０(重量％) (2)ステアリルアルコール １５．０ (3)ラウリル硫酸ナトリウム １．０ (4)パラオキシ安息香酸ブチル ０．１ (5)Ｌ−アルギニンコレステロールエステル ０．５ (6)精製水 ５８．４ (1)〜(4)の油相成分を混合し７５℃に加熱して溶解，均
一化する。７５℃に加熱した(6)に油相成分を添加して
乳化し、冷却後４０℃にて(5)を添加，混合，均一化す
る。[Example 3] O / W type emulsion ointment (1) White petrolatum 25.0 (wt%) (2) Stearyl alcohol 15.0 (3) Sodium lauryl sulfate 1.0 (4) Paraoxybenzoic acid Butyl 0.1 (5) L-arginine cholesterol ester 0.5 (6) Purified water 58.4 The oil phase components of (1) to (4) are mixed and heated to 75 ° C. to dissolve and homogenize. The oil phase component is added to (6) heated to 75 ° C to emulsify, and after cooling, (5) is added, mixed and homogenized at 40 ° C.
【００２８】 ［実施例４］Ｏ／Ｗ乳化型美容液 (1)スクワラン ５．０(重量％) (2)白色ワセリン ２．０ (3)ミツロウ ０．５ (4)ソルビタンセスキオレエート ０．８ (5)ポリオキシエチレンオレイルエーテル(20EO) １．２ (6)プロピレングリコール ５．０ (7)パラオキシ安息香酸メチル ０．１ (8)精製水 ５９．８ (9)カルボキシビニルポリマー1.0重量％水溶液 ２０．０ (10)水酸化カリウム ０．１ (11)エタノール ５．０ (12)Ｌ−アルギニンガラクトセレブロシド ０．３ (13)香料 ０．２ (1)〜(5)の油相成分を混合し７５℃に加熱して溶解，均
一化する。一方(6)〜(8)の水相成分を混合，溶解して７
５℃に加熱し、前記の油相成分を添加して予備乳化す
る。(9)を添加した後ホモミキサーにて均一に乳化し、
(10)を加えてｐＨを調整する。冷却後４０℃にて(11)〜
(13)を添加，混合，均一化する。[Example 4] O / W emulsion type beauty essence (1) Squalane 5.0 (% by weight) (2) White petrolatum 2.0 (3) Beeswax 0.5 (4) Sorbitan sesquioleate 0. 8 (5) Polyoxyethylene oleyl ether (20EO) 1.2 (6) Propylene glycol 5.0 (7) Methyl paraoxybenzoate 0.1 (8) Purified water 59.8 (9) Carboxyvinyl polymer 1.0% by weight Aqueous solution 20.0 (10) Potassium hydroxide 0.1 (11) Ethanol 5.0 (12) L-Arginine galactocerebroside 0.3 (13) Perfume 0.2 Add oil phase components of (1) to (5) Mix and heat to 75 ° C to dissolve and homogenize. On the other hand, mix (6) to (8) water phase components and dissolve to
The mixture is heated to 5 ° C., the above oil phase component is added, and pre-emulsified. After adding (9), emulsify uniformly with a homomixer,
(10) is added to adjust the pH. After cooling at 40 ℃ (11) ~
Add (13), mix, and homogenize.
【００２９】 ［実施例５］Ｗ／Ｏ乳化型クリーム (1)ミツロウ ３．０(重量％) (2)吸着精製ラノリン １０．０ (3)スクワラン ３０．０ (4)固形パラフィン ２．０ (5)マイクロクリスタリンワックス ５．０ (6)アジピン酸ヘキシルデシル １０．０ (7)セスキオレイン酸ソルビタン ３．５ (8)ポリオキシエチレン硬化ヒマシ油(50EO) １．０ (9)1,3-ブチレングリコール ５．０ (10)精製水 ２９．３ (11)パラオキシ安息香酸メチル ０．２ (12)Ｌ−アルギニンオクチルエステル １．０ (1)〜(8)の油相成分を混合し７５℃に加熱して溶解，均
一化する。一方(9)〜(11)の水相成分を混合，溶解して
７５℃に加熱し、前記の油相成分に添加してホモミキサ
ーにて均一に乳化する。冷却後４０℃にて(12)を添加，
混合する。[Example 5] W / O emulsion type cream (1) Beeswax 3.0 (wt%) (2) Adsorption-purified lanolin 10.0 (3) Squalane 30.0 (4) Solid paraffin 2.0 ( 5) Microcrystalline wax 5.0 (6) Hexyldecyl adipate 10.0 (7) Sorbitan sesquioleate 3.5 (8) Polyoxyethylene hydrogenated castor oil (50EO) 1.0 (9) 1,3- Butylene glycol 5.0 (10) Purified water 29.3 (11) Methyl paraoxybenzoate 0.2 (12) L-arginine octyl ester 1.0 Mix the oil phase components of (1) to (8) at 75 ° C. Heat to dissolve and homogenize. On the other hand, the aqueous phase components (9) to (11) are mixed and dissolved, heated to 75 ° C., added to the above oil phase components, and uniformly emulsified by a homomixer. After cooling, add (12) at 40 ℃,
Mix.
【００３０】 ［実施例６］Ｏ／Ｗ乳液 (1)ミツロウ ０．７(重量％) (2)スクワラン ５．０ (3)ポリオキシエチレン硬化ヒマシ油(50EO) ２．０ (4)精製水 ６１．８ (5)1,3-ブチレングリコール ５．０ (6)パラオキシ安息香酸メチル ０．２ (7)1%カルボキシメチルセルロース水溶液 ２０．０ (8)エタノール ５．０ (9)Ｌ−アルギニングルコシド ０．３ (1)〜(3)の油相成分を混合，溶解して均一とし、７５℃
に加熱する。一方、(4)〜(6)を混合，溶解して７５℃に
加熱し、これに上記油相成分を添加して予備乳化した
後、(7)を加えてホモミキサーにて均一に乳化する。そ
の後冷却し、４０℃で、(8),(9)を添加する。Example 6 O / W Emulsion (1) Beeswax 0.7 (wt%) (2) Squalane 5.0 (3) Polyoxyethylene hydrogenated castor oil (50EO) 2.0 (4) Purified water 61.8 (5) 1,3-Butylene glycol 5.0 (6) Methyl paraoxybenzoate 0.2 (7) 1% aqueous carboxymethylcellulose solution 20.0 (8) Ethanol 5.0 (9) L-arginine glucoside 0.3 (1) ~ (3) oil phase components are mixed and dissolved to homogenize, 75 ℃
Heat to On the other hand, (4) to (6) are mixed, dissolved and heated to 75 ° C., the above oil phase component is added to the mixture for preliminary emulsification, and then (7) is added and uniformly emulsified with a homomixer. . After cooling, (8) and (9) are added at 40 ° C.
【００３１】 ［実施例７］ローションタイプ養毛剤 (１)１，３−ブチレングリコール ２．０(重量％) (２)グリセリン １．０ (３)塩化ステアリルトリメチルアンモニウム ０．５ (４)メチルフェニルポリシロキサン １．０ (５)コラーゲン加水分解物 １．０ (６)エタノール ５０．０ (７)パラオキシ安息香酸メチル ０．２ (８)精製水 ４３．８ (11)Ｌ−アルギニンリゾホスファチジン酸エステル ０．５ (１)〜(12)の全成分を混合均一化する。[Example 7] Lotion type hair nourishing agent (1) 1,3-butylene glycol 2.0 (% by weight) (2) glycerin 1.0 (3) stearyl trimethyl ammonium chloride 0.5 (4) methylphenyl poly Siloxane 1.0 (5) Collagen hydrolyzate 1.0 (6) Ethanol 50.0 (7) Methyl paraoxybenzoate 0.2 (8) Purified water 43.8 (11) L-arginine lysophosphatidic acid ester 0 .5 Mix and homogenize all components (1) to (12).
【００３２】本発明の実施例及び、−アルギニンエステ
ルを等モルのＬ−アルギニンに置き換えた比較例を用い
て、マウスの血流促進効果の測定を行った。剃毛したマ
ウス背部に実施例及び比較例を塗布し、塗布前及び塗布
後１５分後の血流量の測定を行った。結果を表１に示し
た。その結果、Ｌ−アルギニンをエステル化して配合し
た実施例は、比較例よりも１．５倍程度の血流促進効果
を有していた。このことにより、Ｌ−アルギニンをエス
テル化して配合することで、Ｌ−アルギニンの経皮透過
性が高まり、少量の配合で、有効な血流促進効果が得ら
れることがわかった。Using the example of the present invention and a comparative example in which -arginine ester was replaced with equimolar L-arginine, the blood flow promoting effect in mice was measured. The Example and Comparative Example were applied to the shaved back of the mouse, and blood flow was measured before and 15 minutes after the application. The results are shown in Table 1. As a result, the example in which L-arginine was esterified and mixed had a blood flow promoting effect of about 1.5 times that of the comparative example. From this, it was found that by esterifying and blending L-arginine, the transdermal permeability of L-arginine was increased, and an effective blood flow promoting effect was obtained with a small amount of blending.
【表１】 [Table 1]
【００３３】実施例２及び実施例２のＬ−アルギニンエ
ステルを精製水に置き換えた比較例Ａ、Ｌ−アルギニン
エステルを等モルのＬ−アルギニンに置き換えた比較例
Ｂを用いて官能評価を行った。官能評価は、シワ等の老
化症状の気になるパネル各１０人に実施例２及び比較例
Ａ，Ｂをそれぞれ１日２回，３カ月間連続使用してもら
い、３カ月後の肌状態についてアンケート調査を行っ
た。官能評価の結果を表２に示した。評価結果は、各項
目の回答人数で示した。Sensory evaluation was carried out using Comparative Example A in which the L-arginine ester of Example 2 and Example 2 was replaced by purified water, and Comparative Example B in which the L-arginine ester was replaced by an equimolar amount of L-arginine. . The sensory evaluation was carried out by having 10 people each worried about aging symptoms such as wrinkles use Example 2 and Comparative Examples A and B twice a day for 3 months continuously and about the skin condition after 3 months. We conducted a questionnaire survey. The results of sensory evaluation are shown in Table 2. The evaluation results are shown by the number of respondents in each item.
【００３４】[0034]
【表２】 官能評価の結果、実施例２ではほとんどのパネルで、シ
ワ，ハリ，ツヤ，タルミに改善効果が認められた。一方
比較例Ａでは、効果があるとしたパネルの数はどの項目
でも２０％未満であり 老化症状改善効果はほとんど認
められなかった。Ｌ−アルギニンを配合した比較例Ｂで
は、改善効果があると回答したパネルの数は５０％程度
に増加していたが、実施例２の改善効果にははるかに及
ばない結果となった。このことにより、Ｌ−アルギニン
をエステル化して配合することにより、シワ，ハリ，ツ
ヤ，タルミ等の皮膚老化症状を改善する効果が飛躍的に
向上することが示された。[Table 2] As a result of the sensory evaluation, in almost all of the panels in Example 2, the effect of improving wrinkles, firmness, gloss and tarmi was observed. On the other hand, in Comparative Example A, the number of panels determined to be effective was less than 20% in any item, and almost no effect of improving aging symptoms was observed. In Comparative Example B containing L-arginine, the number of panels that answered that there was an improving effect increased to about 50%, but the result was far below the improving effect of Example 2. From this, it was shown that the effect of improving skin aging symptoms such as wrinkles, firmness, gloss, and tarmi is dramatically improved by esterifying and blending L-arginine.
【００３５】また、実施例７のローションタイプ養毛剤
について、マウスを用いて養毛効果試験を行った。休止
期にあるＣ３系マウス（１群５匹）の背部を剃毛し、実
施例７のローションタイプ養毛剤をそれぞれ１日１回塗
布し、剃毛後２０日における再生毛面積比（再生毛面積
／剃毛面積）を測定した。比較例として、Ｌ−アルギニ
ンエステルを等モルのＬ−アルギニンに置き換えてロー
ションタイプ育毛剤を調製し、実施例と同様の操作を行
った。結果を表３に示した。Further, the lotion-type hair nourishing agent of Example 7 was subjected to a hair nourishing effect test using mice. The backs of C3 mice (5 mice per group) in the resting phase were shaved, and the lotion-type hair nourishing agent of Example 7 was applied once a day, respectively, and the ratio of regenerated hair area 20 days after shaving (regenerated hair area) / Shaving area) was measured. As a comparative example, an L-arginine ester was replaced with an equimolar amount of L-arginine to prepare a lotion-type hair restorer, and the same operation as in Example was performed. The results are shown in Table 3.
【００３６】[0036]
【表３】 表３に示す結果より明らかなように、本発明の実施例７
の再生毛面積比は、０．８以上の値を示しており、比較
例に比べ、顕著な毛の再生が見られることがわかる。[Table 3] As is clear from the results shown in Table 3, Example 7 of the present invention
The ratio of regenerated hair area is 0.8 or more, which shows that remarkable regenerated hair is observed as compared with the comparative example.
【００３７】なお、上記の使用期間において、実施例を
使用した群において、痛み、痒み等の皮膚刺激やアレル
ギー反応等の皮膚症状を訴えたパネラーはいなかった。
また、乳化状態の悪化や配合成分の沈降，変質等も認め
られなかった。During the above-mentioned period of use, no panelists complained of skin irritation such as pain and itching, or skin symptoms such as allergic reaction in the group using the examples.
In addition, no deterioration of the emulsified state, no sedimentation and deterioration of the components were observed.
【００３８】[0038]
【発明の効果】以上詳述したように、本発明により、Ｌ
−アルギニンエステルを血流促進剤として配合すること
により、非常に優れた老化防止効果及び養毛効果を発揮
する皮膚外用剤を提供することができる。本発明に係る
皮膚外用剤においては、有効成分であるＬ−アルギニン
が良好に経皮吸収され、表皮基底層からさらには真皮に
まで到達でき、低濃度の配合で優れた老化防止効果及び
養毛効果を示すものと考えられる。As described above in detail, according to the present invention, L
By blending arginine ester as a blood flow promoting agent, a skin external preparation that exhibits a very excellent anti-aging effect and hair-growth effect can be provided. In the external preparation for skin according to the present invention, L-arginine, which is an active ingredient, is satisfactorily transdermally absorbed, can reach the dermis from the epidermis basal layer, and has excellent anti-aging effect and hair growth with a low concentration. It is considered to show an effect.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 ＦＩ 技術表示箇所 Ａ６１Ｋ 7/06 Ａ６１Ｋ 7/06 7/48 7/48 31/575 31/575 31/66 ＡＤＳ 31/66 ＡＤＳ 31/685 ＡＤＡ 31/685 ＡＤＡ 31/70 31/70 Ｃ０７Ｈ 15/04 Ｃ０７Ｈ 15/04 Ｄ Ｃ０７Ｊ 9/00 Ｃ０７Ｊ 9/00 ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification code Internal reference number FI Technical display area A61K 7/06 A61K 7/06 7/48 7/48 31/575 31/575 31/66 ADS 31 / 66 ADS 31/685 ADA 31/685 ADA 31/70 31/70 C07H 15/04 C07H 15/04 D C07J 9/00 C07J 9/00
Claims (6)
ル若しくはアルケニルエステル、リン脂質エステル、ス
フィンゴシン及びその誘導体のエステル、糖脂質エステ
ル、糖エステル、ステロールエステルを有効成分とする
血流促進剤。1. A blood flow promoter comprising an alkyl or alkenyl ester of L-arginine having 6 to 20 carbon atoms, a phospholipid ester, an ester of sphingosine and its derivative, a glycolipid ester, a sugar ester, or a sterol ester as an active ingredient.
して配合した皮膚外用剤。2. A skin external preparation containing the blood flow promoting agent according to claim 1 as an active ingredient.
して配合した化粧料。3. A cosmetic containing the blood flow promoter according to claim 1 as an active ingredient.
して配合した老化防止用化粧料。4. A cosmetic for anti-aging containing the blood flow promoter according to claim 1 as an active ingredient.
して配合した頭皮用化粧料。5. A scalp cosmetic containing the blood flow promoter according to claim 1 as an active ingredient.
して配合した養毛・育毛剤。6. A hair nourishing and hair-growing agent containing the blood flow promoting agent according to claim 1 as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP07966696A JP4020989B2 (en) | 1996-03-06 | 1996-03-06 | Blood flow promoting agent and external preparation for skin comprising the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP07966696A JP4020989B2 (en) | 1996-03-06 | 1996-03-06 | Blood flow promoting agent and external preparation for skin comprising the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH09241156A true JPH09241156A (en) | 1997-09-16 |
| JP4020989B2 JP4020989B2 (en) | 2007-12-12 |
Family
ID=13696502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP07966696A Expired - Fee Related JP4020989B2 (en) | 1996-03-06 | 1996-03-06 | Blood flow promoting agent and external preparation for skin comprising the same |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4020989B2 (en) |
Cited By (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999045900A1 (en) * | 1998-03-11 | 1999-09-16 | Kabushiki Kaisha Soken | Skin normalizing agents |
| JP2000327560A (en) * | 1999-05-18 | 2000-11-28 | Noevir Co Ltd | Bathing agent composition |
| JP2001026514A (en) * | 1999-06-16 | 2001-01-30 | Exsymol Sam | Cosmetic composition for slimming |
| WO2001055098A1 (en) * | 2000-01-28 | 2001-08-02 | The Procter & Gamble Company | Palatable arginine compounds and uses thereof for cardiovascular health |
| JP2002003373A (en) * | 2000-06-27 | 2002-01-09 | Shiseido Co Ltd | Skin care preparation |
| JP2006273808A (en) * | 2005-03-30 | 2006-10-12 | Naris Cosmetics Co Ltd | Skin whitening cosmetic |
| WO2006109888A1 (en) * | 2005-04-13 | 2006-10-19 | Shiseido Company, Ltd. | Antiwrinkle agent |
| EP1714650A1 (en) * | 2005-03-31 | 2006-10-25 | Ajinomoto Co., Inc. | Arginine-containing compositions for increasing blood flow |
| JP2006306865A (en) * | 2005-03-31 | 2006-11-09 | Ajinomoto Co Inc | Arginine-containing composition for increasing blood flow |
| JP2009526753A (en) * | 2005-12-30 | 2009-07-23 | ルバンス セラピュティックス インク． | Arginine heteromer for topical administration |
| AU2006203098B2 (en) * | 1998-03-11 | 2009-10-08 | Kabushiki Kaisha Soken | Skin conditioner |
| JP2009242396A (en) * | 2008-03-28 | 2009-10-22 | L'oreal Sa | Composition containing combination of madecassoside and/or terminoloside, as well as arginine and/or salt and/or derivative thereof; use of the combination for inducing and/or stimulating growth of human keratinous fiber, and/or for preventing loss of human keratinous fiber |
| US7629384B2 (en) * | 1997-09-17 | 2009-12-08 | Strategic Science & Technologies, Llc | Topical delivery of L-arginine to cause beneficial effects |
| US7829593B2 (en) | 2006-09-29 | 2010-11-09 | Ajinomoto Co., Inc. | Glutamine-containing compositions and a method for increasing blood flow using same |
| US7914814B2 (en) | 1997-09-17 | 2011-03-29 | Strategic Science & Technologies, Llc | Topical delivery of arginine of cause beneficial effects |
| WO2013017361A1 (en) * | 2011-08-03 | 2013-02-07 | Evonik Goldschmidt Gmbh | Use of sphinganine to improve the visual appearance of skin and hair |
| US9050365B2 (en) | 2004-04-19 | 2015-06-09 | Strategic Science & Technologies, Llc | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
| US9072659B2 (en) | 2009-06-24 | 2015-07-07 | Strategic Science & Technologies, Llc | Topical composition containing naproxen |
| US9155701B2 (en) | 2009-06-24 | 2015-10-13 | Strategic Science & Technologies, Llc | Delivery of ibuprofen and other compounds |
| US9226909B2 (en) | 2004-04-19 | 2016-01-05 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
| US9289495B2 (en) | 2010-12-29 | 2016-03-22 | Strategic Science & Technologies, Llc | Systems and methods for treatment of allergies and other indications |
| US9381146B2 (en) | 1998-03-11 | 2016-07-05 | Kabushiki Kaisha Soken | Skin conditioner |
| US9463158B2 (en) | 2009-06-24 | 2016-10-11 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| JP2019137650A (en) * | 2018-02-14 | 2019-08-22 | 株式会社 リトル・サイエンティスト | Cosmetic containing arginine ester |
| WO2022265053A1 (en) * | 2021-06-19 | 2022-12-22 | 株式会社アジュバンホールディングス | Hair growth stimulant |
| WO2022265054A1 (en) * | 2021-06-19 | 2022-12-22 | 株式会社アジュバンホールディングス | Hair growth stimulant |
| US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
-
1996
- 1996-03-06 JP JP07966696A patent/JP4020989B2/en not_active Expired - Fee Related
Cited By (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7914814B2 (en) | 1997-09-17 | 2011-03-29 | Strategic Science & Technologies, Llc | Topical delivery of arginine of cause beneficial effects |
| US7629384B2 (en) * | 1997-09-17 | 2009-12-08 | Strategic Science & Technologies, Llc | Topical delivery of L-arginine to cause beneficial effects |
| US9381146B2 (en) | 1998-03-11 | 2016-07-05 | Kabushiki Kaisha Soken | Skin conditioner |
| WO1999045900A1 (en) * | 1998-03-11 | 1999-09-16 | Kabushiki Kaisha Soken | Skin normalizing agents |
| AU2006203098B2 (en) * | 1998-03-11 | 2009-10-08 | Kabushiki Kaisha Soken | Skin conditioner |
| JP2000327560A (en) * | 1999-05-18 | 2000-11-28 | Noevir Co Ltd | Bathing agent composition |
| JP2001026514A (en) * | 1999-06-16 | 2001-01-30 | Exsymol Sam | Cosmetic composition for slimming |
| WO2001055098A1 (en) * | 2000-01-28 | 2001-08-02 | The Procter & Gamble Company | Palatable arginine compounds and uses thereof for cardiovascular health |
| US6794375B2 (en) * | 2000-01-28 | 2004-09-21 | The Procter & Gamble Co. | Palatable arginine compounds and uses thereof for cardiovascular health |
| JP2002003373A (en) * | 2000-06-27 | 2002-01-09 | Shiseido Co Ltd | Skin care preparation |
| US9226909B2 (en) | 2004-04-19 | 2016-01-05 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
| US9050365B2 (en) | 2004-04-19 | 2015-06-09 | Strategic Science & Technologies, Llc | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
| JP2006273808A (en) * | 2005-03-30 | 2006-10-12 | Naris Cosmetics Co Ltd | Skin whitening cosmetic |
| JP2006306865A (en) * | 2005-03-31 | 2006-11-09 | Ajinomoto Co Inc | Arginine-containing composition for increasing blood flow |
| US8445536B2 (en) | 2005-03-31 | 2013-05-21 | Ajinomoto Co., Inc. | Arginine-containing compositions and methods for increasing blood flow using same |
| EP1714650A1 (en) * | 2005-03-31 | 2006-10-25 | Ajinomoto Co., Inc. | Arginine-containing compositions for increasing blood flow |
| WO2006109888A1 (en) * | 2005-04-13 | 2006-10-19 | Shiseido Company, Ltd. | Antiwrinkle agent |
| KR101496373B1 (en) * | 2005-12-30 | 2015-02-26 | 레반스 테라퓨틱스, 아이엔씨. | Arginine heteromers for topical administration |
| US8628756B2 (en) | 2005-12-30 | 2014-01-14 | Revance Therapeutics, Inc. | Arginine heteromers for topical administration |
| JP2009526753A (en) * | 2005-12-30 | 2009-07-23 | ルバンス セラピュティックス インク． | Arginine heteromer for topical administration |
| US8815954B2 (en) * | 2005-12-30 | 2014-08-26 | Revance Therapeutics, Inc. | Arginine heteromers for topical administration |
| JP2013028633A (en) * | 2005-12-30 | 2013-02-07 | Revance Therapeutics Inc | Arginine heteromer for use in topical administration |
| US7829593B2 (en) | 2006-09-29 | 2010-11-09 | Ajinomoto Co., Inc. | Glutamine-containing compositions and a method for increasing blood flow using same |
| JP2009242396A (en) * | 2008-03-28 | 2009-10-22 | L'oreal Sa | Composition containing combination of madecassoside and/or terminoloside, as well as arginine and/or salt and/or derivative thereof; use of the combination for inducing and/or stimulating growth of human keratinous fiber, and/or for preventing loss of human keratinous fiber |
| US9457092B2 (en) | 2009-06-24 | 2016-10-04 | Strategic Science & Technologies, Llc | Delivery of ibuprofen and other compounds |
| US10172865B2 (en) | 2009-06-24 | 2019-01-08 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| US9161915B2 (en) | 2009-06-24 | 2015-10-20 | Strategic Science & Technologies, Llc | Delivery of ibuprofen and other compounds |
| US9072659B2 (en) | 2009-06-24 | 2015-07-07 | Strategic Science & Technologies, Llc | Topical composition containing naproxen |
| US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| US10898489B2 (en) | 2009-06-24 | 2021-01-26 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| US10682357B2 (en) | 2009-06-24 | 2020-06-16 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| US9463158B2 (en) | 2009-06-24 | 2016-10-11 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| US9492458B2 (en) | 2009-06-24 | 2016-11-15 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| US9155701B2 (en) | 2009-06-24 | 2015-10-13 | Strategic Science & Technologies, Llc | Delivery of ibuprofen and other compounds |
| US9675619B2 (en) | 2009-06-24 | 2017-06-13 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| US9737543B2 (en) | 2009-06-24 | 2017-08-22 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| US9498482B2 (en) | 2010-12-29 | 2016-11-22 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| US9833456B2 (en) | 2010-12-29 | 2017-12-05 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| US9289495B2 (en) | 2010-12-29 | 2016-03-22 | Strategic Science & Technologies, Llc | Systems and methods for treatment of allergies and other indications |
| WO2013017361A1 (en) * | 2011-08-03 | 2013-02-07 | Evonik Goldschmidt Gmbh | Use of sphinganine to improve the visual appearance of skin and hair |
| CN103764108A (en) * | 2011-08-03 | 2014-04-30 | 赢创德固赛有限公司 | Use of sphinganine to improve the visual appearance of skin and hair |
| JP2019137650A (en) * | 2018-02-14 | 2019-08-22 | 株式会社 リトル・サイエンティスト | Cosmetic containing arginine ester |
| WO2022265053A1 (en) * | 2021-06-19 | 2022-12-22 | 株式会社アジュバンホールディングス | Hair growth stimulant |
| WO2022265054A1 (en) * | 2021-06-19 | 2022-12-22 | 株式会社アジュバンホールディングス | Hair growth stimulant |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4020989B2 (en) | 2007-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4020989B2 (en) | Blood flow promoting agent and external preparation for skin comprising the same | |
| EP1600143B1 (en) | SKIN PREPARATION FOR EXTERNAL USE CHARACTERIZED BY CONTAINING SUGAR DERIVATIVE OF a,a-TREHALOSE | |
| KR101355343B1 (en) | Skin treatment composition | |
| KR100881611B1 (en) | External preparation | |
| JP2003503436A (en) | Oligosaccharide aldonic acids and their topical use | |
| RU2442563C2 (en) | The compositions containing the proteins for the transfer/recycling the structurally modified lipids and their application | |
| WO2008110942A1 (en) | Cosmetic formulations | |
| KR20030026233A (en) | Skin cleanser containing anti-aging active | |
| WO2002083087A1 (en) | Sugar intake promoters | |
| JP3758794B2 (en) | Collagen production promoter and anti-aging skin external preparation containing the same | |
| KR102610937B1 (en) | Crosslinked hyaluronic acid compositions and method of producing the same | |
| JPH06305932A (en) | Skin external agent | |
| JPH0995432A (en) | Preparation for external use for skin | |
| CA2508093A1 (en) | Preparation for external use on skin | |
| JPH04270212A (en) | Skin external agent | |
| JP3568983B2 (en) | Hair restorer | |
| JP3505003B2 (en) | External preparation | |
| JPH07215839A (en) | Skin external agent | |
| JP4193016B2 (en) | Skin preparation | |
| JP2004131403A (en) | Skin care preparation for external use | |
| JPH07138125A (en) | Dermal agent for external use | |
| US20060030621A1 (en) | Preparation for external use on skin | |
| JPH0665053A (en) | External preparation for skin | |
| JP3526497B2 (en) | Body composition | |
| JP2001302435A (en) | Preparation for external use for skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070213 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070413 |
|
| RD05 | Notification of revocation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7425 Effective date: 20070413 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070920 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070926 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101005 Year of fee payment: 3 |
|
| R150 | Certificate of patent (=grant) or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101005 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111005 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111005 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121005 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121005 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131005 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |